Molecular Diagnostics Market Trends, Growth, Size, Analysis, Revenue, Challenges, Future Outlook
Molecular Diagnostics Market Growth, Size, Trends Analysis - By Product, By Test Location, By Technology, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jan-2025 | Report ID: HLCA2508 | Pages: 1 - 261 | Formats*: |
| Category : Healthcare | |||
Molecular Diagnostics Market Introduction and Overview
According to SPER Market Research, the Global Molecular Diagnostics Market is estimated to reach USD 39.08 billion by 2034 with a CAGR of 4.26%.
The market is expanding due in large part to technological advancements, an aging population, and a growing need for accurate and effective genetic testing. Additionally, increased patient awareness of the advantages of quicker diagnostic results and a growing need for self-diagnostic tools are driving the growing popularity of Point-of-Care (POC) testing. Businesses are being encouraged by this trend to create and launch new testing products. Additionally, the market for molecular diagnostics is expanding due to the increased prevalence of infectious diseases and different types of cancer. Further propelling market expansion are developments in biomarker discovery and heightened understanding and acceptance of personalized medicine. However, Due to their high cost, only reference labs and major hospitals with substantial capital budgets can afford to buy molecular diagnostic technologies. Lacking adequate funding, many smaller labs, medical practices, and private practitioners could not be able to purchase these pricey, massive analyzers. Therefore, the high prices may prevent the market for molecular diagnostics from expanding.
Recent Developments:
- In 2024: The FDA approved Danaher's (US) dual-target molecular diagnostic test, Xpert Xpress GBS, in March 2024 for the qualitative intrapartum detection of Group B Streptococcus (GBS).
- The BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel from bioMérieux (France) received US FDA 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval in March 2024.
By Product: Based on product, reagents segment dominated the market.
The reagents segment held the largest market share in 2024, driven by the increasing demand for accurate and efficient diagnostic tools across various healthcare sectors. Reagents, including enzymes, probes, primers, and buffers, are crucial for molecular diagnostic tests. Continuous innovation and new product launches by key players further contribute to the segment's growth.
By Test Location: The central laboratories segment held the largest market share in 2024
The central laboratories segment dominated the market in 2024, holding the largest revenue share at 78.8%. This dominance stems from advancements in laboratory technology, such as automation and integration, which significantly improve testing efficiency and throughput. Central laboratories excel at handling high-volume testing, facilitating faster and more accurate diagnoses. Their crucial role in disease detection, monitoring, and personalized medicine continues to drive market growth. Secondly, the self-test or OTC segment is projected to experience the most rapid growth during the forecast period. This growth is primarily driven by a rising consumer preference for at-home health monitoring solutions
By Technology: Based on technology, the PCR segment led the market with the largest revenue.
The PCR segment led the market, holding the largest revenue share in 2024. PCR encompasses various methods, including quantitative PCR, reverse transcription PCR, and multiplex PCR, with multiplex PCR gaining popularity due to its ability to detect multiple targets simultaneously. Real-time PCR has become crucial for cancer marker analysis, driving the increased use of high-throughput PCR techniques in cancer detection. Further driving segment expansion has been the advancement of digital PCR technologies.
By Application: The infectious disease segment led the market with the largest revenue share
The infectious disease segment held the largest market share in 2024, driven by the increasing demand for rapid and accurate pathogen detection. Molecular diagnostic techniques like PCR and next-generation sequencing have revolutionized infectious disease identification, allowing healthcare providers to diagnose conditions like tuberculosis, HIV, and various viral infections more efficiently than traditional methods. Key market players contribute to the growth of the infectious disease segment by developing innovative, rapid, and accurate diagnostic technologies.
By Region: The greatest market share for Molecular Diagnostics Market is held by the North America region.
North America led the molecular diagnostic market in 2024, holding the largest revenue share. This dominance is attributed to the increasing adoption of molecular diagnostics, recognized for their superior accuracy, sensitivity, and specificity. The rising demand for genetic testing, particularly for personalized healthcare in conditions like diabetes and cancer, is expected to drive market growth. Furthermore, increasing regulatory support for advanced solutions further contributes to market expansion.
Market Competitive Landscape
The Global Molecular Diagnostics Market is highly consolidated. Some of the market players are Abbott, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., BIOMÉRIEUX, Danaher, F. Hoffmann-La Roche, Ltd., Grifols, Hologic Inc. (Gen Probe), Illumina, Inc., QIAGEN, Siemens Healthineers AG, Sysmex Corporation, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Test Location, By Technology, By Application. |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe. |
| Companies Covered | Abbott, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., BIOMÉRIEUX, Danaher, F. Hoffmann-La Roche, Ltd., Grifols, Hologic Inc. (Gen Probe), Illumina, Inc., QIAGEN, Siemens Healthineers AG, Sysmex Corporation, Others. |
Key Topics Covered in the Report:
- Global Molecular Diagnostics Market Size (FY’2021-FY’2034)
- Overview of Global Molecular Diagnostics Market
- Segmentation of Global Molecular Diagnostics Market By Product (Instruments, Regards, Others)
- Segmentation of Global Molecular Diagnostics Market By Test Location (Point of care, Self-test or OTC, Central laboratories)
- Segmentation of Global Molecular Diagnostics Market By Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-Generation Sequencing, In Situ Hybridization, DNA Microarrays, Other)
- Segmentation of Global Molecular Diagnostics Market By Application (Oncology, Pharmacogenomics, Infectious disease, Genetic Testing, Neurological disease, Cardiovascular disease, Microbiology, Others)
- Statistical Snap of Global Molecular Diagnostics Market
- Expansion Analysis of Global Molecular Diagnostics Market
- Problems and Obstacles in Global Molecular Diagnostics Market
- Competitive Landscape in the Global Molecular Diagnostics Market
- Details on Current Investment in Global Molecular Diagnostics Market
- Competitive Analysis of Global Molecular Diagnostics Market
- Prominent Players in the Global Molecular Diagnostics Market
- SWOT Analysis of Global Molecular Diagnostics Market
- Global Molecular Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Molecular Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Molecular Diagnostics Market
7. Global Molecular Diagnostics Market, By Product (USD Million) 2021-2034
7.1. Instruments7.2. Regards7.3. Others
8. Global Molecular Diagnostics Market, By Test Location (USD Million) 2021-2034
8.1. Point of care8.2. Self-test or OTC8.3. Central laboratories
9. Global Molecular Diagnostics Market, By Technology (USD Million) 2021-2034
9.1. Polymerase Chain Reaction9.2. Isothermal Nucleic Acid Amplification Technology9.3. DNA Sequencing & Next-Generation Sequencing9.4. In Situ Hybridization9.5. DNA Microarrays9.6. Other
10. Global Molecular Diagnostics Market, By Application (USD Million) 2021-2034
10.1. Oncology
10.1.1. Breast Cancer10.1.2. Prostate Cancer10.1.3. Colorectal Cancer10.1.4. Cervical10.1.5. Kidney10.1.6. Liver10.1.7. Blood10.1.8. Lung10.1.9. Other
10.2. Pharmacogenomics10.3. Infectious disease
10.3.1. MRSA10.3.2. Clostridium difficile10.3.3. Vancomycin-resistant enterococci10.3.4. Carbapenem-resistant bacteria testing10.3.5. Flu10.3.6. Respiratory syncytial virus (RSV)10.3.7. Candida10.3.8. Tuberculosis and drug-resistant TB10.3.9. Meningitis10.3.10. Gastro-intestinal panel testing10.3.11. Chlamydia10.3.12. Gonorrhea10.3.13. HIV10.3.14. Hepatitis C10.3.15. Hepatitis B10.3.16. Other Infectious Diseases
10.4. Genetic Testing
10.4.1. Newborn screening10.4.2. Predictive and presymptomatic testing10.4.3. Others
10.5. Neurological disease10.6. Cardiovascular disease10.7. Microbiology10.8. Others
11. Global Molecular Diagnostics Market (USD Million) 2021-2034
11.1. Global Molecular Diagnostics Market Size and Market Share
12. Global Molecular Diagnostics Market, By Region (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. Abbott
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments
13.2. Agilent Technologies, Inc.
13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments
13.3. BD
13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments
13.4. Bio-Rad Laboratories, Inc.
13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments
13.5. BIOMÉRIEUX
13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments
13.6. Danaher
13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments
13.7. F. Hoffmann-La Roche, Ltd.
13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments
13.8. Grifols
13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments
13.9. Hologic Inc. (Gen Probe)
13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments
13.10. Illumina, Inc.
13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments
13.11. QIAGEN
13.11.1. Company details13.11.2. Financial outlook13.11.3. Product summary13.11.4. Recent developments
13.12. Siemens Healthineers AG
13.12.1. Company details13.12.2. Financial outlook13.12.3. Product summary13.12.4. Recent developments
13.13. Sysmex Corporation
13.13.1. Company details13.13.2. Financial outlook13.13.3. Product summary13.13.4. Recent developments
13.14. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Molecular Diagnostics Market is projected to reach USD 39.08 billion by 2034, growing at a CAGR of 4.26% during the forecast period.
Molecular Diagnostics Market grew in Market size from 2025. The Market is expected to reach USD 39.08 billion by 2034, at a CAGR of 4.26% during the forecast period.
Molecular Diagnostics Market CAGR of 4.26% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Molecular Diagnostics Market size is USD 39.08 billion from 2025 to 2034.
Molecular Diagnostics Market is covered By Product, By Test Location, By Technology, By Application.
The North America is anticipated to have the highest Market share in the Molecular Diagnostics Market.
The key players in the Market include Companies Covered Abbott, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., BIOMÉRIEUX, Danaher, F. Hoffmann-La Roche, Ltd., Grifols, Hologic Inc. (Gen Probe), Illumina, Inc., QIAGEN, Siemens Healthineers AG, Sysmex Corporation, Others.
The market is expanding due in large part to technological advancements, an aging population, and a growing need for accurate and effective genetic testing. Additionally, increased patient awareness of the advantages of quicker diagnostic results and a growing need for self-diagnostic tools are driving the growing popularity of Point-of-Care (POC) testing.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
